contributes to the difficulty in devising therapies to substantially improve the clinical course of patients with PAH.
Neurohumoral input modulates the behavior of many of these implicated cell types, and autonomic dysregulation (enhanced sympathetic activity and parasympathetic withdrawal) characterizes many cardiovascular diseases, including heart failure with reduced ejection fraction (HFrEF) and PAH (7) (8) (9) .
Beta-adrenergic blockers are standard of care for patients with HFrEF and increase survival in this setting; however, the use of beta-adrenergic blockers for PAH remains controversial (10) . The renin-angiotensin-aldosterone system (RAAS) is upregulated in PH (5). Indeed, elevated plasma levels of RAAS hormones (aldosterone in humans with PAH [11] and angiotensin II in a monocrotalineinduced dog model of PH [12] ) have been reported.
Mineralocorticoid antagonism in rodents attenuates
experimental PH and pulmonary vascular remodeling (13) , and renal sympathetic denervation in dogs suppresses RAAS activation and prevents monocrotaline-induced PH (12) . Pulmonary artery denervation reduces pulmonary artery pressure in thromboxane A 2 -induced PH in pigs (14) and was reported to improve clinical outcomes in patients with PH/PAH (15) . However, controversy regarding methodological and ethical issues in the latter study has arisen (16) .
In contrast to these efforts to inhibit sympathetic activity in PH, little is known regarding the therapeutic efficacy in PH of restoring autonomic balance by enhancement of parasympathetic activation.
Pyridostigmine is an acetylcholinesterase inhibitor that augments parasympathetic activity, is widely 
